29 mei, 2019
Welcome to the first newsletter for the DORA trial. Future issues will be distributed quarterly, with special issues produced for major study-related announcements. We have now activated 15 sites out of 30-40 and randomized 12 patients out of 738. DORA investigator meeting at ASCO (details in newsletter). Phase I/IIa trial data published in European Journal of Cancer (Morris MJ, et al. Eur J Cancer. 2019 May 10;114:107-116.).
Dr. Michael Morris discusses the study’s aims.
Our first Dutch site, Erasmus MC, is now open for enrollment! Dr. Ronald de Wit is the overall PI for the Netherlands.